Search Results for: Tikun Olam

New Study: Children With Autism See Improvement After Treatment With Tikun Olam High-CBD, Low-THC Medical Cannabis

NEW YORK: Children with Autism Spectrum Disorder (ASD) see a “significant” improvement in symptoms and less reliance on other medications after treatment with Tikun Olam’s Avidekel™ medical cannabis, as confirmed by a new study published in Scientific Reports.

The two-year study, “Real Life Experience Of Medical Cannabis Treatment In Autism: Analysis Of Safety And Efficacy,” followed 188 children (average age: 13) diagnosed with ASD. The patients were treated with Tikun Olam’s high-CBD, low-THC medical cannabis strains, which have been specifically cultivated and shown to provide symptom relief for ASD and related conditions with minimal psychoactive effect.

At the study’s outset, the most common patient symptoms were restlessness (90.4%), rage attacks (79.8%), and agitation (78.7%). After six months of daily cannabis treatment at Tikun Olam clinics in Israel, 80.1% of patients reported improvement of their symptoms, with 30.1% reporting “significant” improvement. Other key findings include:

  • Of 27 patients who had epilepsy, 24 reported improved or disappearance of symptoms;
  • 34% of patients decreased other medications; and
  • 20% of patients stopped using antipsychotic medication.

“Autism is a leading condition of concern worldwide, so this study couldn’t have come at a better time,” says Dr. Annabelle Manalo, PhD, Tikun Olam’s Science Director. “The data shows that autism patients can improve their overall quality of life utilizing a high CBD strain, and most importantly, that young users can safely and effectively benefit from medical cannabis.”

“With this study, cannabis is shown to be an effective choice for parents looking for the safest and most neuroprotective treatment.”

Side effects to cannabis treatment were minimal, with the most common at six months reported as restlessness (6.6%), sleepiness (3.2%), psychoactive effect (3.2%).

Tikun Olam Teams With iaso To Serve Puerto Rico

PUERTO RICO: Tikun Olam will soon have a presence in Puerto Rico, according to a company press release. Through an exclusive licensing agreement with iaso Corporation,  a leading San Juan-based science and technology company, Tikun products and strains, including the widely researched high-CBD Avidekel, will be distributed s throughout the Commonwealth in 2019.  The arrangement with iaso is the tenth struck in the United States by Tikun Olam’s US joint venture, TO Global.
iaso is Puerto Rico’s only all-indoor cultivation facility, employing soil-less, aeroponic technology.

Tikun products to be distributed throughout PR in 2019.

Tikun products to be distributed throughout PR in 2019.

“iaso is an ideal partner for Tikun’s values and mission,” says Tikun USA CEO Bernard Sucher. “César Cordero-Krüger has accomplished so much for his community, in business and philanthropy.  We are privileged to work with his team of professionals dedicated to advancing the science of cannabis.”

“Tikun’s proprietary cultivars are shown to treat patients in a safe, effective, and consistent manner,” says iaso founder and CEO César Cordero-Krüger. “This partnership advances iaso’s mission to become a trusted provider of cannabis products to Puerto Rican patients.”

Tikun Olam and Ilera Healthcare Announce Pennsylvania Partnership

PENNSYLVANIA and NEW YORK:  Tikun Olam, the world leader in cannabis science, and Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser, have finalized a deal to bring Tikun’s world-renowned medical marijuana strains to medical cannabis patients in the Keystone State later this year.

This partnership combines Tikun Olam’s history of peer-reviewed scientific research and unprecedented clinical data collection with Ilera’s expertise in formulating and delivering high-quality pharmaceutical-grade medical cannabis products to Pennsylvanians. Products developed from Tikun Olam’s proprietary strains, including its world-renowned Avidekel high-CBD strain, will be available in vape oils, tinctures and topical formulations.

Tikun Olam has created numerous cannabis strains designed to deliver symptomatic relief for specific conditions in line with the 17 medical conditions approved for medical cannabis use in Pennsylvania, including autism, cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy, to name a few.
“Tikun Olam has spent years developing our strains through scientific methods,” says Tikun CEO Bernie Sucher. “Finding the ideal partner that shares our focus on quality control and consistency from seed to sale was a top priority for our Pennsylvania launch, and Ilera Healthcare was our top choice.”
Greg Rochlin, CEO of Ilera Healthcare, sees this as a natural partnership. “Ilera is dedicated to producing consistent, high-quality medications with effects that are supported by data, and so is Tikun Olam.”

Tikun Olam Announces Closing Of $7 Million Convertible Promissory Notes Financing

NEW YORK: Tikun Olam USA, the world pioneer in cannabis research, is pleased to announce the closing of a $7,000,000 offering of 6% convertible promissory notes (the “Notes”), maturing in March 2019.

Proceeds from the Notes, issued by T.O. Global LLC, a New York limited liability company (the “Company”), will be used for product research and development, enhancing and protecting intellectual property, patient studies and trials, advertising and marketing of the Company’s brand, payment of corporate, organizational and transactional expenses, repayment of indebtedness to a related party, and working capital and general corporate purposes.

This financing highlights recent major licensing deals for the Company that will bring its exclusive, branded, science-backed cannabis products to more than ten U.S. states, from coast to coast in 2018.

About Tikun Olam

Tikun Olam (“repair the world” in Hebrew) is a leading cannabis brand and globally recognized as the pioneer of modern medical cannabis.  The company’s global mission is to research, develop and provide efficacious, data-based cannabis treatments to help sufferers. Operating as a commercial venture for over ten years, Tikun Olam’s products have been used since 2010 in ongoing clinical trials in Israel’s regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn’s Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy.

Israel’s Tikun Olam Continues U.S. Expansion

Deal with DC Cultivator Alternative Solutions Brings Renowned Cannabis Products to the Nation’s Capital 

NEW YORK:  Tikun Olam, a leading Israeli cannabis brand and pioneer in cannabis research, continues its U.S. expansion by partnering with Washington DC cultivator Alternative Solutions. The just-inked licensing deal allows Alternative Solutions to grow, manufacture and distribute Tikunbranded products to all five District of Columbia dispensaries.

Tikun Olam’s award-winning premium cannabis products are backed by years of peer-reviewed scientific research and unprecedented clinical data collection, which has shown to deliver symptomatic relief to those suffering from specific conditions such as cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy, to name a few. At the  held November 30 in Toronto, Tikun strains took First place in three categories: Top High THC Flower (Eran Almog), Top High CBD Flower  (Avidekel), and Top High CDB Oil (Avidekel), in addition to placing Second in Top Hybrid Flower (Midnight). Tikun’s full line of proprietary strain products–from flower, vape, topicals and tinctures–will be available in Washington DC  beginning in 2018.

“Alternative Solutions is thrilled to be Tikun Olam’s exclusive partner in DC,” says Matt Lawson-Baker, COO of Alternative Solutions. “We look forward to making Tikun’s products available at all DC dispensaries, giving access to these clinically proven strains to the more than 5,600 registered MMJ patients in Washington DC.”

The new five-year deal with Alternative Solutions is the latest in a series of licensing agreements struck since Tikun’s U.S. launch in 2015 in Delaware. The recent announcement with the MariMed cannabis network will introduce Tikun’s exclusive strains and products in medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun™ products also launched in Nevada in March 2017 and in Washington State in November.

Cannabis Science Pioneer Tikun Olam Expands Partnership With MariMed

Combines Tikun Products & Unparalleled Research with MariMed’s Cultivation & Distribution Networks

MASSACHUSETTS and NEW YORK:  Tikun Olam, the world pioneer in cannabis research, and MariMed Inc., a preeminent management company in the U.S. medical cannabis industry, announced an expansion of their licensing agreement for Tikun Olam products to be grown, manufactured and sold through MariMed’s network of managed and affiliated licensed facilities throughout the United States.

This new agreement brings Tikun Olam’s premium cannabis products, years of proprietary, peer-reviewed scientific research and unprecedented clinical data collection to four additional MMJ-legal U.S. states, its most expansive agreement to date. Tikun Olam and MariMed’s relationship began in 2015 with a pilot program in Delaware and marked the first time that U.S. patients had access to the world’s only cannabis strains proven to deliver symptomatic relief for specific conditions including cancer, PTSD, epilepsy, Crohn’s Disease/Colitis, chronic pain and neuropathy to name a few.

“After the great success of our program in Delaware, MariMed is excited to bring Tikun™ to our expanding national network of legal cannabis production and dispensary facilities,” says Robert Fireman, CEO of MariMed Inc. “Tikun Olam’s empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun’s products to tens of thousands of new patients nationwide.”

MariMed will introduce Tikun’s exclusive strains and products in state-of-the-art, regulatory compliant and fully operational cultivation and medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products will be available in flower, vape cartridges, topicals, tinctures and edibles utilizing at least six Tikun-branded strains, including its world-renowned Avidekel high-CBD strain.  In addition to Delaware, Tikun products have launched in Nevada (March 2017) and are expected to launch Washington (November 2017).

“Tikun Olam is delighted to expand our relationship with MariMed,” says Tikun CEO Bernard Sucher.  “MariMed utilizes the “best practices” and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before.”

Tikum Olam Launches Tikun Hemp

NEW YORK:  Tikun Olam, the global pioneer in cannabis science and medicine, announces the launch of Tikun Hemp™, its first hemp-based product line, available exclusively in the United States. Tikun Hemp offerings include broad-spectrum CBD tinctures, topicals and softgel capsules, all shipped directly to consumers via the Tikun Hemp website.

“Tikun’s mission is in its name to “repair the world,” says Bernie Sucher, CEO of Tikun Olam USA. “We bring to our Tikun Hemp products nearly two decades of cannabinoid knowledge and R&D, including identifying the anti-inflammatory properties of CBD and ongoing clinical trials and research. We are very pleased to share this knowledge and expertise directly with Americans nationwide through Tikun Hemp.”

The world’s first licensed cannabis company, Tikun Olam is the recognized leader in cannabis research and developed the world’s first-ever, high-CBD, low-THC, cannabis varietal Avidekel™ to treat adult and child patients alike with broad-spectrum cannabinoids without a psychoactive effect. Tikun Hemp is the first hemp-based product to bear the trusted Tikun name.

Tikun Hemp is grown in full compliance with the 2018 US Farm Bill and is certified by the Colorado Department of Public Health and Environment. All Tikun Hemp products are triple-tested, gluten-free, non-GMO and completely THC-free, and shipped directly to consumers in 47 states. As part of its rigorous control processes, Tikun Hemp products are tested in no less than three key stages of the supply chain to ensure safe and quality broad-spectrum CBD products.

“Broad-spectrum” means all the naturally occurring compounds, including terpenes, found in the cannabis plant, except for THC. Studies have shown that using the whole plant preserves natural compounds that creates an “entourage effect,” increasing the therapeutic benefits.

“Our Tikun Hemp products are built on the back of our groundbreaking  medical cannabis research, and like our cannabis products are rigorously tested throughout the process to ensure they are safe and effective,” says Chris Gallant, Tikun SVP, Consumer.  “We are incredibly excited to be able to put the trusted Tikun name behind a THC-free product that can be available to people across the United States.”

Tikun Olam (“repair the world” in Hebrew) is the world’s leading cannabis brand and pioneer of modern medical cannabis. Its products have been used since 2010 to treat over 20,000 patients for symptoms of medical conditions including cancer, PTSD, AIDS, epilepsy, Crohn’s Disease/colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy. Tikun cannabis products are available in the United States and Puerto Rico in accordance with local law; visit tikunolamusa.com for more information.

Maryland Medical Cannabis Forum Is Thursday, November 8, 2018

Presents an In-Depth Discussion of MMJ Research and Practice

MARYLAND – Maryland doctors can enhance their knowledge about medical cannabis treatment at the inaugural Maryland Medical Cannabis Forum (MMCF), on Thursday, November 8th in Baltimore.  The MMCF was created to provide to the Maryland medical community current and credible information on the state of medical cannabis research and practices–and how it affects the 35,000-and-growing Maryland MMJ patients. Discussion topics for the evening include:

  • The endocannabinoid system and its relation to treating diseases
  • Cancer case studies utilizing cannabis for symptom relief and pain management
  • Cannabis treatment for neurological disorders such as Alzheimer’s, epilepsy and autism
  • Cannabis and reduction in opioid dependency and other prescription medications
  • Proper dosing and understanding common side effects

The evening kicks off at 5:00 p.m. with a cocktail and hors d’oeuvres reception. The program begins at 6:30 p.m. with featured speakers Dr. Jokūbas Žiburkus (Canntelligence) and Dr. Dustin Sulak (Healer.com), followed by a panel discussion hosted by CNBC’s Tim Seymour and including Sid Taubenfeld of Tikun Olam’s TO Pharma and Joy Strand, Executive Director of the Maryland Medical Cannabis Commission, among others.

The MMCF is proud to have the support of MedChi (the Maryland State Medical Society), and sponsors including global medical cannabis brand Tikun Olam, MariMed Advisors and Kind Therapeutics to establish this event as a comprehensive and trustworthy forum for up-to-date information on medical cannabis for Maryland doctors to provide their patients. The registration fee for MMCF is $75, $50 for MedChi members; visit www.medicalcannabisforum.org.

Legal Marijuana Market Worth $146.4 Billion By 2025

CALIFORNIA: The global legal marijuana market is expected to reach USD 146.4 billion by end of 2025, according to a new report by Grand View Research, Inc. Growing adoption of marijuana in several medical applications such as cancer, mental disorders, chronic pain and others is expected to propel revenue growth in near future.

Legal marijuana has started gaining traction worldwide due to very high demand among consumers and increasing legalization of recreational or medical marijuana in various countries. Additionally, high public and private investment for research and the development of safer forms of ingesting marijuana such as tinctures, oils, vapes and other edibles are expected to positively reinforce market growth. The number of conditions treated using medical marijuana is growing rapidly, as new patients are added to the market, the demand for medical marijuana is expected to increase multiple folds over the forecast period. Countries like Canada and the U.S. are moving towards legalization of marijuana for recreational purposes, this in turn is expected to create a shift form medical to recreational marijuana. Lengthy purchase and approval process for medical marijuana prescription and ease of availability of recreational marijuana is expected to trigger this this change.

Increasing number of companies operating in the marijuana market is expected to bolster the quantity and variety of products reaching the end users. Products like marijuana oil have started gaining traction over the past few years owing to increased effectiveness and safety as compared to smoking it. Also, the growing research in cannabis industry has led to introduction of new marijuana strains. These advances in new product development is expected to enhance product adoption among consumers. Legal marijuana market is witnessing strong technological and information exchange. Countries like Canada, the U.S., Germany and Australia are expected to emerge as leading markets in terms of sale, whereas, countries like Israel are focusing on research and technology development and are leveraging on knowledge transfer.

Key Findings From the Report:

    • The U.S. legal marijuana market size was estimated at USD 7.06 billion in 2016 and is expected to grow at a CAGR of 24.9% from 2017 to 2025
    • Medical marijuana emerged as the largest marijuana type segment in 2016 and is estimated to be valued at USD 100.03 billion by 2025
    • By product type, marijuana buds segment was estimated to be dominant in 2016 with revenue share of 62.9% and is estimated to be valued at USD 82.9 billion by end of 2025
    • Some players operating in legal marijuana market are Canopy Growth Corporation, Aphria, Inc., Aurora Cannabis, Maricann Group, Inc., Tilray, The Cronos Group, Organigram Holdings, Inc, ABcann Medicinals, Inc., and Tikun Olam

Browse full research report with TOC on “Legal Marijuana Market Size, Share & Trends Analysis Report By Type (Medical, Recreational), By Product Type, By Medical Application (Chronic Pain, Mental Disorders, Cancer), And Segment Forecasts, 2018 – 2025” at: https://www.grandviewresearch.com/industry-analysis/legal-marijuana-market

New Study: Cannabis: Safe & Effective Medical Treatment

NEW YORK: For the first time, a major scientific study has confirmed what cannabis advocates have known for decades: that cannabis can be a safe and effective palliative treatment in patients suffering from the debilitating effects of cancer.

The article, “Prospective Analysis Of Safety And Efficacy Of Medical Cannabis In Large Unselected Population Of Patients With Cancer” just published in the European Journal of Internal Medicine, studied thousands of cancer patients at Tikun Olam clinics in Israel.  The patients were prescribed cannabis for their “malignancy-related symptoms,” mainly sleep problems, pain, nausea, and decreased appetite. All patients were prescribed one or more of Tikun Olam’s proprietary cannabis strains, which were developed to address specific symptoms. Overall, the study encompassed 2,970 cancer patients, with an average age of 60,  and treated between  the years 2015 and 2017.

Tikun Olam published the following: 95.9% of respondents reported an improvement in their condition through use of medical cannabis, leading the study’s authors to conclude that “Cannabis as a palliative treatment for cancer patients is a well-tolerated, effective and safe option.” In medical terms, palliative treatment in cancer patients is aimed mainly to alleviate pain and nausea.

The article also offers hope in the fight against the U.S. opioid epidemic. While opioids were the most consumed drug by patients at intake, at six months, 36% had stopped taking opioids entirely, and an additional 10% decreased their dosage. This is especially significant because 51% of the patients studied were suffering from Stage 4 cancers, and 52% reported their pain at an intense (8/10) level.

“The data establishes that cannabis is effective treatment for the most acute symptoms of cancer, such as pain, which often requires the use of opioids,” said  Lihi Bar-Lev Schleider of Tikun Olamand lead author of the article.

Side effects were sparse and minor: the most common reported at one month were dizziness (8%), dry mouth (7.3%), increased appetite (3.6%), sleepiness (3.3%) and psychoactive effect (2.8%).

On the other hand, improvement was undisputed: at six months, 50.8% of respondents reported at least a significant improvement, 45.1% reported moderate or slight improvement and only 4.0% did not experience a positive effect.

Tikun Olam’s Pharmaceuticals division (TOP) along with its Canadian joint venture partner, Jay Pharma, as well as  Israel’s Soroka University Medical Center, Ben-Gurion University of the Negev, and the Hebrew University of Jerusalem were proud to collaborate together for this unprecedented affirmation by the scientific community of the efficacy of medical marijuana.